These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32891803)

  • 1. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease.
    Nastasi DR; Moxon JV; Norman R; Trollope AF; Rowbotham S; Quigley F; Jenkins J; Golledge J
    J Vasc Surg; 2021 Apr; 73(4):1396-1403.e3. PubMed ID: 32891803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm.
    Nastasi DR; Norman R; Moxon JV; Quigley F; Velu R; Jenkins J; Golledge J
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):643-650. PubMed ID: 34507892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitor valuation: A science-based review of the two recent models.
    Baum SJ; Cannon CP
    Clin Cardiol; 2018 Apr; 41(4):544-550. PubMed ID: 29512936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
    Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K
    J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
    Virani SS; Akeroyd JM; Nambi V; Michos ED; Morris PB; Nasir K; Smith SC; Stone NJ; Petersen LA; Ballantyne CM
    Circulation; 2019 Jan; 139(3):410-412. PubMed ID: 30586689
    [No Abstract]   [Full Text] [Related]  

  • 13. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
    Dressel A; Schmidt B; Schmidt N; Laufs U; Fath F; Chapman MJ; Grammer TB; März W
    Vascul Pharmacol; 2019 Sep; 120():106566. PubMed ID: 31207358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.